Recent clinical data suggests that Novera Retatrutide, a dual-action treatment from Novo Nordisk, could offer a substantial step in weight control. Unlike many existing treatments, Retatrutide affects both glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), potent